Residency · Residency · Nephrology

Post-Transplant Complications and Long-Term Management

Introduction

Kidney transplant recipients face a unique spectrum of medical complications arising from the interplay of chronic immunosuppression, the transplanted organ itself, and pre-existing comorbidities that preceded the transplant. Although long-term graft and patient survival have improved substantially over the past several decades, cardiovascular disease, infections, and malignancy remain the major threats to post-transplant longevity. A structured, systematic approach to long-term follow-up is essential, encompassing regular monitoring of graft function, immunosuppressive drug levels, and proactive screening for the complications outlined in this chapter.

Early Post-Transplant Complications (First 3 Months)

Delayed Graft Function (DGF)

Delayed graft function is defined as the need for dialysis within the first week after transplantation. It occurs in 20 to 30 percent of deceased donor transplants but in fewer than 5 percent of living donor transplants, reflecting the favorable conditions of minimal cold ischemia and planned procurement in the living donor setting. The primary mechanism is ischemia-reperfusion injury sustained during organ procurement, preservation, and implantation. Risk factors include prolonged cold ischemia time exceeding 24 hours, donation after cardiac death (DCD) donors, expanded criteria donors, kidneys procured from donors with acute kidney injury, recipient sensitization with high PRA, and perioperative hypotension.

Management of DGF requires maintaining full immunosuppression, as rejection and DGF can coexist and DGF does not protect against the alloimmune response. If graft function does not improve by 7 to 10 days, a transplant biopsy should be performed to exclude concurrent rejection, thrombotic microangiopathy, or other treatable causes. Dialysis support is provided as needed during the recovery period. DGF is clinically significant because it increases the risk of subsequent acute rejection and is associated with reduced long-term graft survival.

Surgical Complications

Vascular complications, though relatively infrequent, can be devastating. Renal artery thrombosis occurs in fewer than 1 percent of cases and typically results in immediate graft loss. Renal vein thrombosis, occurring in 1 to 2 percent of transplants, presents with graft swelling, hematuria, and rising creatinine and requires emergency thrombectomy or may lead to graft loss. Renal artery stenosis develops in 1 to 5 percent of recipients, classically presenting with refractory hypertension, an audible bruit over the graft, and rising creatinine. Diagnosis is established by Doppler ultrasonography demonstrating elevated peak systolic velocities, and treatment consists of percutaneous angioplasty with or without stenting.

Urologic complications include ureteral leak, occurring in 2 to 5 percent of cases and typically resulting from ischemic necrosis of the distal ureter, which derives its blood supply solely from the renal artery rather than from a separate ureteral branch. Treatment involves ureteral stenting or surgical revision. Ureteral stricture develops in 2 to 10 percent of transplants and is managed with balloon dilation or surgical reimplantation. Lymphocele, a peritransplant fluid collection resulting from transected lymphatic channels, occurs in 1 to 18 percent of cases and may compress the ureter or iliac vessels, causing hydronephrosis or lower extremity edema; symptomatic lymphoceles require percutaneous drainage or surgical fenestration into the peritoneal cavity.

Wound complications, including hematoma, seroma, and wound infection, are more common in recipients receiving mTOR inhibitors (which impair wound healing), in obese patients, and in those with diabetes.

Primary Non-Function

Primary non-function describes a graft that never achieves function, necessitating graft nephrectomy and return to dialysis. Causes include hyperacute rejection (now rare with routine crossmatch testing), extensive cortical necrosis from donor-related factors, and vascular catastrophes such as arterial or venous thrombosis.

Infections

Timeline of Post-Transplant Infections

Post-transplant infections follow a predictable temporal pattern that reflects the evolution of immunosuppressive intensity and immune reconstitution. During the first month, nosocomial and donor-derived infections predominate, including surgical site infections, urinary tract infections, Clostridioides difficile colitis, and donor-transmitted infections. From months 1 through 6, the period of maximal immunosuppression, opportunistic infections become the principal concern: cytomegalovirus, BK polyomavirus, Pneumocystis jirovecii, Aspergillus, Nocardia, Listeria, and Toxoplasma. Beyond 6 months, as immunosuppression is reduced to maintenance levels, community-acquired infections such as urinary tract infections, pneumonia, influenza, and COVID-19 predominate, though late opportunistic infections can still occur in patients who are over-immunosuppressed.

CMV (Cytomegalovirus)

Cytomegalovirus is the most clinically important viral infection after kidney transplantation. The highest risk group is the donor-seropositive, recipient-seronegative (D+/R-) combination, in which 60 to 80 percent of recipients will develop CMV disease without prophylaxis. Recipients who are seropositive (R+) are at intermediate risk from reactivation of latent virus. Clinical manifestations range from asymptomatic viremia to a systemic syndrome with fever, leukopenia, and malaise, and to tissue-invasive disease affecting the gastrointestinal tract (colitis, esophagitis), lungs (pneumonitis), liver (hepatitis), and eyes (retinitis).

Prevention employs one of two strategies. Universal prophylaxis with valganciclovir 900 mg daily is administered for 6 months in D+/R- recipients and for 3 months in R+ recipients. Alternatively, a preemptive strategy monitors CMV viral load by PCR weekly and initiates treatment only when viremia is detected. Treatment of established CMV disease consists of valganciclovir 900 mg twice daily for a minimum of 3 weeks, with concurrent reduction in immunosuppression, particularly mycophenolate. Intravenous ganciclovir is preferred for severe disease or gastrointestinal involvement where oral absorption may be compromised. CMV resistance, typically mediated by UL97 mutations conferring ganciclovir resistance, necessitates salvage therapy with foscarnet or maribavir, the latter having received FDA approval for refractory CMV. Letermovir, a CMV terminase inhibitor approved for CMV prophylaxis in hematopoietic stem cell transplantation, is under active investigation for solid organ transplant recipients.

BK Polyomavirus (BKV)

BK polyomavirus reactivation occurs from latent virus residing in renal tubular epithelial cells that proliferates under the permissive conditions of immunosuppression. Ten to 30 percent of kidney transplant recipients develop BK viremia, and 1 to 10 percent progress to BK-associated nephropathy (BKVAN), which threatens graft survival. The clinical presentation is a rising serum creatinine without other explanation; definitive diagnosis requires transplant biopsy demonstrating viral cytopathic changes with characteristic ground-glass nuclear inclusions and positive SV40 immunostaining.

Screening for BK viremia by quantitative PCR is recommended every 1 to 3 months for the first 2 years post-transplant. BK viruria exceeding 10 to the seventh copies per mL is suggestive but nonspecific, whereas BK viremia exceeding 10 to the fourth copies per mL indicates a high risk for nephropathy and warrants intervention. The cornerstone of treatment is immunosuppression reduction: mycophenolate is reduced first, followed by tacrolimus dose reduction of 25 to 50 percent. No antiviral therapy has proven efficacy; cidofovir and leflunomide have limited supporting evidence and are not routinely recommended, while IVIG is employed at some centers. The management of BK nephropathy requires a careful balancing act between the competing risks of uncontrolled viral replication, which destroys the graft, and over-reduction of immunosuppression, which precipitates rejection.

Pneumocystis jirovecii (PJP)

Prophylaxis against Pneumocystis jirovecii pneumonia is a universal standard of care after kidney transplantation. Trimethoprim-sulfamethoxazole (TMP-SMX), administered as a single-strength tablet daily or a double-strength tablet three times weekly, is the preferred agent for the first 6 to 12 months post-transplant, with some centers continuing prophylaxis indefinitely in high-risk patients. TMP-SMX offers the additional benefit of providing concurrent prophylaxis against Toxoplasma, Nocardia, Listeria, and urinary tract infections. For patients unable to tolerate TMP-SMX, alternatives include dapsone, atovaquone, or inhaled pentamidine, though none offer the same breadth of coverage.

<image>Timeline diagram of post-transplant infections organized by time period after kidney transplantation. Show three phases on a horizontal timeline: Phase 1 (0-1 month): nosocomial infections (wound infection, UTI, C. difficile, donor-transmitted infections). Phase 2 (1-6 months): opportunistic infections (CMV with peak incidence at months 2-4, BK virus with peak at months 2-6, PJP, Aspergillus, Nocardia, Listeria, Toxoplasma). Phase 3 (>6 months): community-acquired infections (UTI, pneumonia, influenza, COVID-19) and late opportunistic infections in over-immunosuppressed patients. Include a prevention timeline below showing: valganciclovir prophylaxis (months 0-3 or 0-6), TMP-SMX prophylaxis (months 0-6 to 0-12), BK virus screening schedule (monthly months 1-12, then every 3 months), and CMV monitoring. Color-code by organism type: bacterial (red), viral (blue), fungal (green), parasitic (purple).</image>

Cardiovascular Disease

Epidemiology

Cardiovascular disease is the leading cause of death in kidney transplant recipients with a functioning graft, accounting for approximately 40 percent of all deaths. The cardiovascular risk in transplant recipients is 3 to 5 times higher than in the age-matched general population, though substantially lower than the risk that persists in patients remaining on dialysis. Traditional cardiovascular risk factors are highly prevalent in this population and are compounded by immunosuppression-specific contributions to cardiometabolic risk.

Immunosuppression-Related CV Risk

Calcineurin inhibitors contribute to cardiovascular risk through multiple mechanisms: tacrolimus and cyclosporine both cause hypertension through renal vasoconstriction, tacrolimus is a stronger driver of new-onset diabetes after transplant than cyclosporine, while cyclosporine produces more dyslipidemia than tacrolimus. mTOR inhibitors are potent inducers of dyslipidemia, particularly hypertriglyceridemia and hypercholesterolemia. Corticosteroids promote diabetes, dyslipidemia, central obesity, and hypertension. Sirolimus can cause proteinuria, which may independently worsen cardiovascular risk.

Management

Hypertension management targets a blood pressure below 130/80 mmHg. Calcium channel blockers are generally preferred as first-line agents because they do not affect calcineurin inhibitor metabolism and provide effective blood pressure reduction. ACE inhibitors and ARBs should be avoided during the first 3 months post-transplant due to the risk of hyperkalemia and acute kidney injury in the early graft, but they become valuable tools after graft stabilization for their antiproteinuric and cardiovascular protective effects.

Dyslipidemia is managed with statin therapy, which is recommended for all transplant recipients over 30 years of age. The ALERT trial demonstrated that fluvastatin reduced the secondary endpoint of cardiac death and non-fatal myocardial infarction in renal transplant recipients. Drug interactions are an important consideration: cyclosporine significantly increases statin levels, and simvastatin should be avoided in combination with cyclosporine; low-dose atorvastatin, rosuvastatin, or pravastatin are preferred alternatives.

Post-transplant diabetes mellitus (PTDM, formerly NODAT) develops in 10 to 40 percent of kidney transplant recipients, with tacrolimus and corticosteroids being the primary drivers. Screening with fasting plasma glucose and oral glucose tolerance testing should be performed at 3, 6, and 12 months post-transplant and annually thereafter. Management follows a stepwise approach: lifestyle modification, insulin for early glycemic control, metformin if eGFR is above 30, and increasingly, SGLT2 inhibitors and GLP-1 receptor agonists, though transplant-specific data remain limited and monitoring for urinary tract infections and euglycemic diabetic ketoacidosis is warranted with SGLT2 inhibitors.

Malignancy

Epidemiology

Transplant recipients carry a 3 to 5 times increased overall cancer risk compared to the general population. The most common malignancies are non-melanoma skin cancers, with squamous cell carcinoma dramatically exceeding basal cell carcinoma (a reversal of the general population ratio) and a 65- to 250-fold increased SCC risk. Post-transplant lymphoproliferative disorder, Kaposi sarcoma, renal cell carcinoma in native kidneys, and cervical and anogenital cancers related to human papillomavirus are also substantially overrepresented.

Post-Transplant Lymphoproliferative Disorder (PTLD)

PTLD represents a spectrum of abnormal lymphoid proliferations ranging from benign polyclonal B-cell hyperplasia to aggressive monoclonal lymphoma, driven by Epstein-Barr virus in the setting of T-cell immunosuppression that permits unchecked B-cell proliferation. The incidence is 1 to 3 percent in adults and up to 10 percent in children, who are more often EBV-naive. The highest risk group is EBV D+/R-, followed by recipients who receive potent T-cell depleting induction with rATG. Clinical presentation includes lymphadenopathy, mass lesions (with the gastrointestinal tract being the most common extranodal site), constitutional symptoms, elevated LDH, and rising EBV viral load.

The first step in treatment is reduction of immunosuppression, which achieves a response in 20 to 80 percent of cases of early PTLD. For aggressive or monomorphic PTLD, rituximab combined with CHOP chemotherapy is the standard approach. Conversion from CNI-based to mTOR inhibitor-based immunosuppression may provide an additional anti-proliferative benefit. EBV viral load should be monitored monthly for the first year in EBV-seronegative recipients to detect early EBV reactivation.

Skin Cancer Prevention

Annual comprehensive dermatologic examination is recommended for all transplant recipients. Aggressive sun protection with SPF 50 or higher sunscreen and protective clothing is essential. For patients who develop recurrent squamous cell carcinomas, the TUMORAPA trial demonstrated that conversion from CNI-based to sirolimus-based immunosuppression achieved a 50 percent reduction in new SCC development, establishing a clear role for mTOR inhibitors in the secondary prevention of post-transplant skin cancer.

Chronic Allograft Nephropathy (Interstitial Fibrosis/Tubular Atrophy - IFTA)

Causes

The histologic finding of interstitial fibrosis and tubular atrophy (IFTA) represents the final common pathway of multiple injuries to the allograft. Chronic active antibody-mediated rejection is the most common cause of progressive late graft loss. CNI nephrotoxicity produces a characteristic pattern of chronic arteriolar hyalinosis and "striped fibrosis." Recurrence of the original native kidney disease, including FSGS, IgA nephropathy, membranous nephropathy, diabetic kidney disease, and oxalosis, can damage the allograft. BK nephropathy, chronic T-cell mediated rejection, hypertensive nephrosclerosis, and non-adherence to immunosuppression all contribute to the cumulative burden of IFTA.

Management

Protocol biopsies, performed as surveillance biopsies at 3, 12, and 24 months at some transplant centers, allow detection of subclinical rejection and early IFTA before clinical manifestations appear. Surveillance monitoring for de novo donor-specific antibodies provides an immunologic early warning system. Management of established IFTA focuses on addressing modifiable factors: optimizing blood pressure control, reducing proteinuria with RAAS blockade, and minimizing ongoing CNI toxicity. CNI minimization strategies include reducing the CNI dose while adding an mTOR inhibitor or converting to a belatacept-based CNI-free regimen.

Recurrent Disease in the Allograft

High Recurrence Risk

Several glomerular diseases carry a substantial risk of recurrence in the transplant. Primary FSGS recurs in 30 to 40 percent of allografts, often within hours to days of transplantation, presenting with immediate heavy proteinuria and carrying a graft loss risk of approximately 50 percent. Treatment includes plasmapheresis and rituximab. Atypical hemolytic uremic syndrome, mediated by dysregulated complement activation, has a high recurrence rate unless complement blockade with eculizumab or ravulizumab is administered peri-transplant. Primary hyperoxaluria (type 1) recurs in virtually 100 percent of isolated kidney transplants, necessitating combined liver-kidney transplantation to correct the underlying metabolic defect. MPGN and C3 glomerulopathy demonstrate 50 to 70 percent histologic recurrence. IgA nephropathy recurs histologically in 30 to 60 percent of allografts, though clinically significant graft loss from recurrent IgA occurs in only approximately 10 percent. Diabetic nephropathy recurs in virtually all grafts given sufficient time, typically over decades. Membranous nephropathy recurs in 40 to 50 percent of cases, with anti-PLA2R antibody levels serving as a predictor of recurrence risk.

Low Recurrence Risk

ANCA-associated vasculitis recurs in 5 to 10 percent of allografts, and transplantation is generally deferred until disease remission is achieved. Lupus nephritis has a recurrence rate of only 2 to 10 percent, making transplantation an excellent option for lupus patients with ESRD. Anti-GBM disease recurs in fewer than 5 percent of transplants, provided that anti-GBM antibodies have been undetectable for at least 6 to 12 months before transplantation.

<image>Table comparing recurrent glomerular diseases in kidney allografts. Create a visual reference chart with columns for: disease name, recurrence rate, typical timing of recurrence (immediate, months, years), clinical presentation, risk factors for recurrence, impact on graft survival, and prevention/treatment strategies. Include: FSGS (30-40%, immediate, nephrotic syndrome, rapid prior progression is risk, plasmapheresis/rituximab), IgA nephropathy (30-60% histologic, years, hematuria/proteinuria, monitor with biopsy), membranous nephropathy (40-50%, months to years, proteinuria, anti-PLA2R level predicts, rituximab), diabetic nephropathy (nearly 100%, years, proteinuria, glycemic control), aHUS (high without treatment, immediate, TMA, eculizumab), MPGN/C3GN (50-70%, months, proteinuria/hematuria, limited treatment). Use color coding to indicate high-risk (red), moderate-risk (yellow), and low-risk (green) diseases.</image>

Long-Term Monitoring

Routine Follow-Up Schedule

The intensity of post-transplant monitoring follows a tapering schedule that mirrors the declining risk of acute complications over time. During weeks 1 through 4, visits occur 2 to 3 times per week with monitoring of serum creatinine, immunosuppressive drug levels, and complete blood count. During months 2 through 3, the frequency decreases to weekly or biweekly visits. From months 3 through 12, monthly visits are standard. Beyond the second year, visits are spaced to every 2 to 3 months for stable patients, with some centers transitioning to annual visits for patients with excellent long-term stability. At each visit, the essential laboratory panel includes serum creatinine, basic metabolic panel, tacrolimus trough level, complete blood count, urinalysis, and urine protein-to-creatinine ratio.

Screening Protocols

Cancer screening in transplant recipients must be more comprehensive than in the general population. Annual dermatologic examination is mandatory. Age-appropriate cancer screening for colonoscopy, mammography, and cervical cancer screening follows general population guidelines, though some centers advocate earlier or more frequent screening given the elevated cancer risk. Annual abdominal ultrasound of the native kidneys is recommended to screen for renal cell carcinoma, which occurs at an increased rate in ESRD patients. Prostate-specific antigen screening follows the same guidelines as for the general population.

Bone health requires particular attention in transplant recipients, who face increased fracture risk from corticosteroid use, CNI effects on bone, and persistent hyperparathyroidism that may not resolve after successful transplantation. DEXA scanning should be performed, and CKD-mineral and bone disorder management should continue with appropriate monitoring.

Vaccination strategies must account for the immunosuppressed state. Annual influenza vaccination, COVID-19 boosters, pneumococcal vaccination, and hepatitis B vaccination (with potential need for re-vaccination due to impaired antibody responses) are all recommended. Live vaccines, including MMR, varicella, and live zoster (Zostavax), are contraindicated in immunosuppressed patients. The recombinant zoster vaccine (Shingrix) is safe and recommended for appropriate candidates.

Key Clinical Pearls

• BK viremia >10^4 copies/mL requires immunosuppression reduction (reduce MMF first, then tacrolimus); no effective antiviral therapy exists; the key is screening and early intervention
• CVD is the leading cause of death with a functioning graft; aggressive management of hypertension, dyslipidemia, and diabetes post-transplant is essential
• Medication non-adherence is the most common preventable cause of late graft loss; tacrolimus level variability (coefficient of variation >30%) is a sensitive marker of non-adherence and predicts worse outcomes
• Conversion from CNI to mTOR inhibitor should be considered for recurrent non-melanoma skin cancer (TUMORAPA trial) and for CNI nephrotoxicity (if eGFR >40 and minimal proteinuria)
• EBV-seronegative recipients receiving EBV-seropositive organs are at highest risk for PTLD; avoid over-immunosuppression, monitor EBV viral loads, and belatacept is contraindicated in this population

References

1. Fishman JA. Infection in Organ Transplantation. N Engl J Med. 2017;377(25):2500-2514.
2. Hirsch HH, Randhawa PS, AST Infectious Diseases Community of Practice. BK Polyomavirus in Solid Organ Transplantation. Am J Transplant. 2013;13(S4):179-188.
3. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant. 2009;9(S3):S1-S155.
4. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation (TUMORAPA). N Engl J Med. 2012;367(4):329-339.
5. Halloran PF, Reeve J, Akalin E, et al. Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study. Am J Transplant. 2017;17(11):2851-2862.

Read this lecture as Markdown